TECN Share Price Performance
CHF 0
-171.80 (-100.00%)
Price CHF 0
Fair ValueCHF 166.50
Share Pricen/a
Tecan Group AG Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
TECN Community Narratives
AN
Fair Value CHF 166.5 23.7% undervalued intrinsic discount
TECN: Resilient Demand And Share Repurchase Program Will Drive Shareholder Value
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value CHF 335.08 62.1% undervalued intrinsic discount
Lab Automation And Personalized Medicine Will Unlock Secular Opportunities
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value CHF 137 7.3% undervalued intrinsic discount
Tariffs And Disruptions Will Crush Margins While Cuts Will Help
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
TECN: Resilient Demand And Share Repurchase Program Will Drive Shareholder Value
Key Takeaways Rising demand in diagnostics and successful automation launches position Tecan for growth and increased profitability through digital healthcare transformation. Expanding recurring revenues, operational efficiencies, and a sizable share buyback support stable earnings and management's confidence in long-term prospects.Read more
96
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
CHF 166.5
23.7% undervalued intrinsic discount
Fair Value
Profit Margin
8.01%
Future PE
27.06x
Price in 2029
CHF 191.94
Tariffs And Disruptions Will Crush Margins While Cuts Will Help
Key Takeaways Heightened regulatory, compliance, and macroeconomic risks are pressuring margins and clouding growth prospects, with irregular demand and weak visibility on future revenues. Technological shifts and industry digitalization threaten Tecan's competitive edge, while customer concentration and supply chain disruptions further increase earnings instability.Read more
14
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CHF 137
7.3% undervalued intrinsic discount
Fair Value
Revenue
2.73% p.a.
Profit Margin
8.9%
Future PE
21.85x
Price in 2029
CHF 150.44
Lab Automation And Personalized Medicine Will Unlock Secular Opportunities
Key Takeaways Structural cost and manufacturing advantages, combined with strong recurring revenues, position Tecan for expanding margins and resilience against macro and regulatory shocks. Accelerated innovation, increasing commercial adoption, and strategic partnerships drive faster market share gains, enabling robust, sustainable revenue and profit growth.Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CHF 335.08
62.1% undervalued intrinsic discount
Fair Value
Revenue
18.23% p.a.
Profit Margin
6.41%
Future PE
48.55x
Price in 2029
CHF 367.12
Trending Discussion
Recently Updated Narratives
AN
TECN: AI Lab Collaboration Will Support Forward Efficiency Gains And Earnings
Fair Value: CHF 166.5 23.7% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TECN: Mixed Research Views And Investor Day Outlook Shape Future Expectations
Fair Value: CHF 137 7.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TECN: Recent Upgrade And CHF 205 Goal Will Support Higher Long Term P/E
Fair Value: CHF 335.08 62.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Very undervalued with excellent balance sheet and pays a dividend.
2 Risks
4 Rewards
Tecan Group AG Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 11, 2026
- -8.83
- 35.22%
- -12.54%
- 13.1%
About TECN
- Founded
- 1980
- Employees
- 3166
- CEO
- WebsiteView website
Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution. It also provides PARAMIT, a contract design and manufacturing service. Tecan Group AG has a strategic collaboration with NVIDIA Corporation to develop AI-enabled platform for data-driven laboratories to help discoveries and lab productivity. The company was founded in 1980 and is headquartered in Männedorf, Switzerland.
